关键词：高血压；慢性疾病；原发性高血压；继发性高血压
摘 要：Hypertension, also referred to as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Changing lifestyle habits such as poor diet, lack of exercises, and smoking are the major causes of hypertension. Hypertension leads to the damage of organs and can cause several illnesses such as renal failure, aneurysms, heart failure, strokes, and heart attacks. There are two major types of hypertension: primary or essential hypertension and secondary hypertension. The Global Hypertension Drugs market is currently growing at a slow rate and is expected to post a CAGR of 1.20 percent during the forecast period. In 2013, the Americas dominated the market and is expected to continue its dominance during the forecast period. The US was the major revenue contributor to the market in the Americas. The Americas was followed by the EMEA and APAC regions. There is a vast opportunity for vendors in this market to expand into the APAC region.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Rate of Incidence and Prevalence

07.1.1 Americas

07.1.2 The APAC Region

07.1.3 Europe

08. Late-stage Pipeline Snapshot

09. Market Segmentation by Mechanism of

Action

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Actelion Ltd.

19.1.1 Business Overview

19.1.2 Key Information

19.1.3 SWOT Analysis

19.2 AstraZeneca plc

19.2.1 Business Overview

19.2.2 Key Information

19.2.3 SWOT Analysis

19.3 Boehringer Ingelheim GmbH

19.3.1 Business Overview

19.3.2 Business Segmentation

19.3.3 Key Information

19.3.4 SWOT Analysis

19.4 Novartis AG

19.4.1 Business Overview

19.4.2 Business Segmentation

19.4.3 Key Information

19.4.4 SWOT Analysis

19.5 Pfizer Inc.

19.5.1 Business Overview

19.5.2 Business Segmentation

19.5.3 Key Information

19.5.4 SWOT Analysis

19.6 Sanofi SA

19.6.1 Business Overview

19.6.2 Business Segmentation

19.6.3 Key Information

19.6.4 SWOT Analysis

20. Other Reports in this Series